|Articles|January 4, 2023

ICP-MS following EAM 4.7 for Alternative Proteins

Inductively coupled plasma mass spectrometry (ICP-MS) has proven to be an excellent tool for measuring heavy metals and other elements of interest in alternative proteins. A recent study analyzed a range of plant-based and insect-based alternative proteins according to FDA EAM Method 4.7 on the Agilent 7850 ICP-MS with highly successful results. Strategies for achieving confidence in the data were also developed. 


Related to this article

Scientist With Portable Spectrometer in Natural Field Setting ©  By Tika -chronicles-stock.adobe.com
The bulky bench-top NIR spectrometer is quietly being dismantled and rebuilt as a wafer-scale photonic chip, a self-calibrating algorithm, and a sensor small enough to ride in a shirt pocket. What once demanded a grating, a moving mirror, and a climate-controlled lab now fits inside a handheld module, a bioreactor probe, or a drone payload, and it increasingly figures out what it is looking at on its own.
Sizing Up the Nanoscale: Measuring Nanocluster Aerosol in Indoor Air
In the first part of a multi-part Q&A, Brandon Boor, the Dr. Margery E. Hoffman Associate Professor in the Lyles School of Civil and Construction Engineering at Purdue University, describes the instrumentation and methodology behind measuring nanoparticle size distributions at the nanocluster scale (1–3 nm) and outlines the technical challenges of acquiring reliable, real-time data at these dimensions.
Human body wireframe on glowing platform undergoing futuristic body scan. © sergray(noAIelemens) -chronicles-stock.adobe.com
Jurgen Popp, Thomas Mayerhofer, and colleagues at Leibniz IPHT and Friedrich Schiller University Jena introduce the Personalized Optical Digital Twin (PODT), a Photonics21 contribution to Europe's Virtual Human Twin ecosystem that connects molecular photonics—Raman blood analysis, coherent Raman tissue imaging, and multimodal endomicroscopy—with longitudinal physiology and clinical data. Drawing on the published multicenter INTELLIGENCE trials, the authors argue that technical feasibility and clinical utility must be evaluated separately as the field moves toward Europe's FP10 research agenda.